← Zurück zum Screener

Caribou Biosciences

CRBU Micro Cap

Healthcare · Biotechnology

Aktualisiert: Apr 5, 2026, 17:43 UTC

$1.94
-2.51% heute
52W: $0.66 – $3.54
52W Low: $0.66 Position: 44.5% 52W High: $3.54

Kennzahlen

P/E Ratio
—
Kurs/Gewinn-Verhältnis
Forward P/E
—
Erwartetes KGV
P/S Ratio
16.8x
Kurs/Umsatz-Verhältnis
EV/EBITDA
—
Unternehmenswert/EBITDA
Dividendenrendite
—
Jährl. Dividendenrendite
Market Cap
$187.5M
Marktkapitalisierung
Umsatzwachstum
89.7%
YoY Umsatzwachstum
Gewinnmarge
—
Nettomarge
ROE
-78.97%
Eigenkapitalrendite
Beta
2.46
Marktsensitivität
Short Interest
7.64%
% der Aktien leerverkauft
Ø Volumen
1,245,557
Durchschn. Tagesvolumen

Bewertungs-Analyse

Signal
N/A
vs. S&P 500 Ø KGV (24.7x)
Analysten-Konsens
Starker Kauf
8 Analysten
Ø Kursziel
$11.12
+473.45% Upside
Kursziel Spanne
$4.00 – $32.00

Über das Unternehmen

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Sektor: Healthcare Branche: Biotechnology Land: United States Mitarbeiter: 97 Börse: NMS

Trading-Daten

50-Day MA: $1.76
200-Day MA: $1.88
Volumen: 1,061,766
Ø Volumen: 1,245,557
Short Ratio: 4.88
Kurs/Buchwert: 1.51x
Verschuldung/EK: 22.29x
Free Cash Flow: $-69,796,752

Wo kann ich Caribou Biosciences kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.

Nach oben scrollen